If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02164045","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":"true"},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Randomized","arm_groups":[{"arm_group_label":"BMS-663068- Fasted","arm_group_description":"BMS-663068 tablet twice a day by mouth on specified days","arm_type":"Experimental"},{"arm_group_label":"BMS-663068- Fed","arm_group_description":"BMS-663068 tablet twice a day by mouth on specified days","arm_type":"Experimental"}],"assignment":"Crossover Assignment","brief_summary":"The current food effect study is being performed to support a Phase 3 study with BMS 663068. Results from this study will inform whether patients in the upcoming Phase 3 study can be given the flexibility to dose BMS-663068 in the fasted state, if so desired.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:36:22","criteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Healthy subjects as determined by no clinically significant deviation from normal in medical and surgical history, physical examination findings, 12-lead ECG measurements, and clinical laboratory test results - Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive - Males and Females, ages 18 to 50 years, inclusive - Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (HCG)) within 24 hours prior to the start of study drug Exclusion Criteria: - Any significant acute or chronic medical illness as determined by the investigator - Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug - Any major surgery within 4 weeks of study drug administration - Any gastrointestinal surgery that could impact upon the absorption of study drug - Inability to tolerate oral medication - Recent (within 6 months of study drug administration) history of smoking or current smokers - Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiogram (ECG) or clinical laboratory determinations beyond what is consistent with the target population - Any of the following on 12-lead ECG prior to study drug administration, confirmed by repeat: • PR ≥ 210 msec • QRS ≥ 120 msec • QT ≥ 500 msec • QTcF ≥ 450 msec • Positive urine screen for drugs of abuse - Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human Immunodeficiency Virus-1 (HIV-1), -2 antibodies, and HIV-1 RNA","detailed_description":"Primary Purpose: Other: To assess the effect of food on the steady-state exposure of BMS-626529 when administered as BMS 663068 600 mg twice daily (BID) to healthy subjects Acquired Immune Deficiency Syndrome (AIDS)","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"38","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"b332e6dd-ea3b-52b9-981c-f0ee53bd7db0","internal":{"content":null,"contentDigest":"d039f5e0a64f49bafc6c29f3ca40b7ec","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Healthy subjects as determined by no clinically significant deviation from normal in medical and surgical history, physical examination findings, 12-lead ECG measurements, and clinical laboratory test results - Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive - Males and Females, ages 18 to 50 years, inclusive - Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (HCG)) within 24 hours prior to the start of study drug Exclusion Criteria: - Any significant acute or chronic medical illness as determined by the investigator - Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug - Any major surgery within 4 weeks of study drug administration - Any gastrointestinal surgery that could impact upon the absorption of study drug - Inability to tolerate oral medication - Recent (within 6 months of study drug administration) history of smoking or current smokers - Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiogram (ECG) or clinical laboratory determinations beyond what is consistent with the target population - Any of the following on 12-lead ECG prior to study drug administration, confirmed by repeat: • PR ≥ 210 msec • QRS ≥ 120 msec • QT ≥ 500 msec • QTcF ≥ 450 msec • Positive urine screen for drugs of abuse - Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human Immunodeficiency Virus-1 (HIV-1), -2 antibodies, and HIV-1 RNA","interventions":[{"arm_group_label":"BMS-663068- Fasted","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"},{"arm_group_label":"BMS-663068- Fed","intervention_description":"BMS-663068","intervention_name":"BMS-663068","intervention_type":"Drug"}],"interventional_subtype":"Other","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":[],"last_follow_up_date":"07/25/2014 00:00:00","links":[],"locations":[{"City":"San Antonio","Latitude":"29.4854054","CountryDisplay":"United States","Longitude":"-98.4513272","Name":"GSK Investigational Site","StateDisplay":"TX","PostalCode":"78209","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"50 years","maximum_age":"50","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:45:02","number_of_arms":"2","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529 from an Extended-Release Formulation of BMS-663068 in Healthy Subjects","org_study_id":"206283","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"No","fda_regulated_drug":"Yes","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"1","primary_compl_date":"07/25/2014 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Maximum observed concentration (Cmax) for BMS-626529 in the presence and absence of food","outcome_time_frame":"Days 1-4 of Periods 1 and 2","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Area under the concentration-time curve in one dosing interval (AUC(TAU)) for BMS-626529 in the presence and absence of food","outcome_time_frame":"Days 1-4 of Periods 1 and 2","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"AI438-042","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Safety and tolerability endpoints including incidence of Adverse events (AEs), serious AEs, AEs leading to discontinuations, deaths, and the results of vital signs, ECGs, physical examinations, and clinical laboratory tests","outcome_time_frame":"Approximately up to 41 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time of maximum observed plasma concentration (Tmax) of BMS-626529","outcome_time_frame":"Day 4 of each period","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Plasma concentration observed at 12 hours postdose (C12) of BMS-626529","outcome_time_frame":"Day 4 of each period","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Trough observed plasma concentration (Ctrough) of BMS-626529","outcome_time_frame":"Days 1-4 of each period","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"06/24/2014 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"206283"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}